Suzetrigine: A Novel Therapy for Acute Pain and Its Role in Palliative Care

Managing complex pain in patients with serious illness is an integral part of the work of palliative care teams, making it essential for clinicians to stay informed about newly approved pain medications. This ensures patients receive the most current, effective, and evidence-based treatments and care. Journavx (suzetrigine), a non-opioid analgesic, was recently approved by the FDA for the treatment of moderate to severe acute pain in adults. It is the first new class of pain medication to be approved by the FDA since 1998.

This Interprofessional Grand Rounds session, led by Sherika Newman, DO, and Andrea Toufexis Esch, DO, explores the role of Journavx as novel therapy in pain management, with a focus on its efficacy in symptom management, indications, and potential benefits for patients with advanced illness. Presenters will review clinical applications, patient outcomes, and best practices for integration into palliative care treatment plans.